Immunologic Factors: all 3,292 studies that test it
Page 28 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the GingivaCompletedNCT00689143Phase 1
- NIDDM and IR in Combination Therapy for CHCCompletedNCT00687999Not applicable
- Study of TS-1 or TS-1 + PSK for Gastric Cancer PatientsStatus unknownNCT00687843Phase 3
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal TransplantationCompletedNCT00685061Phase 4
- Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological RiskCompletedNCT00682292Phase 3
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal TransplantationCompletedNCT00681343Phase 4
- Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary ImmunodeficiencyCompletedNCT00680446Phase 3
- Allogeneic Transplantation for Pediatric Leukemias With Unrelated DonorsStatus unknownNCT00679536Phase 1/2
- Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute LeukemiaCompletedNCT00678275Phase 3
- A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00674063Phase 3
- A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or InappropriateCompletedNCT00673556Phase 3
- Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase ITerminatedNCT00671801Phase 1
- Autologous Transplant Followed by Allogeneic Transplant for High Risk NeuroblastomaTerminatedNCT00670410Phase 1
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By SurgeryActive, not recruitingNCT00669734Phase 1
- Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and RituximabCompletedNCT00667329Phase 1
- Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's DiseaseCompletedNCT00664599Phase 2
- Chemotherapy and Radiation Following Pancreatic SurgeryCompletedNCT00660270Phase 2
- A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic ArthritisCompletedNCT00659412Phase 2
- IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral LoadStatus unknownNCT00659386Phase 1
- A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusCompletedNCT00657189Phase 2
- Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT00656812Phase 2
- Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)CompletedNCT00656409Phase 3
- Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedNCT00655837Phase 1
- Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)CompletedNCT00655343Phase 3
- A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy VolunteersCompletedNCT00653822Phase 1
- Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By SurgeryCompletedNCT00652860Phase 2
- Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT00645606Phase 3
- Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal TransplantationCompletedNCT00642655Phase 1/2
- Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell LymphomaCompletedNCT00641095Phase 2/3
- Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin LymphomaTerminatedNCT00637832Phase 2
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)Status unknownNCT00628238Phase 2
- Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-AmyloidosisCompletedNCT00621400Phase 1/2
- Vaccine Therapy and GM-CSF in Treating Patients With CNS LymphomaWithdrawnNCT00621036Phase 2
- A Pilot Trial of Rituxan in Refractory Myasthenia GravisCompletedNCT00619671Phase 1/2
- Oral OKT3 in Combination With Beta-D-GlucosylceramideStatus unknownNCT00619372Phase 1
- Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)CompletedNCT00617760Phase 3
- Intravenous Immunoglobulins as Effective Treatment in Sydenham's ChoreaCompletedNCT00615797Not applicable
- Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT00612612Phase 1
- Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus ErythematosusCompletedNCT00611663Phase 2/3
- Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL AmyloidosisCompletedNCT00607581Phase 2
- Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaCompletedNCT00599170Phase 2
- Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaCompletedNCT00598169Phase 1
- Intraoperative Versus Postoperative Thymoglobulin in Lung TransplantationWithdrawnNCT00592306Phase 3
- Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based RegimensCompletedNCT00591188Phase 2
- Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)CompletedNCT00581425Phase 4
- Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same TimeCompletedNCT00581035Phase 4
- A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With MyelodysplasiaCompletedNCT00580242Phase 1
- Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal TransplanationTerminatedNCT00579592Not applicable
- Rituximab for GVHDWithdrawnNCT00578591Phase 2
- Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHLWithdrawnNCT00577161Phase 3
- A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.CompletedNCT00576433Phase 4
- Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent LymphomaCompletedNCT00572013Phase 1/2
- Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung CancerTerminatedNCT00569296Phase 1
- Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV MelanomaCompletedNCT00568763Phase 1
- Value of Rituximab in Humoral Chronic Rejection After Renal TransplantationTerminatedNCT00568477Phase 2
- Rituximab for Prevention of Rejection After Renal TransplantationCompletedNCT00565331Phase 2/3
- A Study of Thymoglobulin and Tacrolimus in Liver TransplantStatus unknownNCT00564538Phase 4
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMPCompletedNCT00564512Phase 3
- Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)CompletedNCT00559702Phase 1
- High-dose Methylprednisolone and Rituximab in High Risk B-CLLCompletedNCT00558181Phase 2
- A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's LymphomaCompletedNCT00556699Phase 1
- Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus ErythematosusCompletedNCT00556192Phase 2
- Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell LymphomaCompletedNCT00556127Phase 2
- An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid ArthritisCompletedNCT00555542Phase 2
- Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple MyelomaCompletedNCT00555100Phase 1
- Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at DiagnosisCompletedNCT00553943Phase 2
- Prospective Trial of Rituximab for Primary Pulmonary Alveolar ProteinosisCompletedNCT00552461Phase 2
- Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT00551928Phase 3
- Rituximab Treatment of Focal Segmental GlomerulosclerosisWithdrawnNCT00550342Phase 2
- Feasibility Study of CDDP + CPT-11 + PSK for Extensive-Stage Disease (ED) Small Cell Lung CancerStatus unknownNCT00546130Phase 2
- A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT00545519Phase 1
- Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen EncephalitisStatus unknownNCT00545493Phase 2/3
- PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and PrednisoneCompletedNCT00544219Not applicable
- Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
- Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver TransplantationCompletedNCT00538265Phase 4
- A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or PolymyositisCompletedNCT00533091Phase 1
- Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.CompletedNCT00532675Phase 1
- Rituximab in Patients With Relapsed or Refractory TTP-HUSStatus unknownNCT00531089Phase 2
- Efficiency and Tolerance of Rituximab (mabthéra) in Bullous PemphigoidCompletedNCT00525616Phase 3
- Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT00525447Phase 1
- IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable DiseaseCompletedNCT00523159Phase 2
- Treatment of Deficient Subclass or Anti-polysaccharide Antibody ResponseCompletedNCT00522821Phase 4
- A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)CompletedNCT00517049Phase 2
- HD18 for Advanced Stages in Hodgkins LymphomaCompletedNCT00515554Phase 3
- Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia GravisCompletedNCT00515450Phase 3
- A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell TransplantTerminatedNCT00515138Early Phase 1
- Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive TractWithdrawnNCT00511212Not applicable
- Rituxan With or Without Methotrexate in Psoriatic ArthritisCompletedNCT00509678Phase 1
- Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent LymphomaCompletedNCT00509379Phase 2
- Rituximab and Involved Field Radiotherapy in Early Stage Follicular LymphomaCompletedNCT00509184Phase 2
- Recombinant Interferon Alpha and Etoposide in Relapsed OsteosarcomaCompletedNCT00504140Phase 2
- Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric CarcinomaTerminatedNCT00503321Phase 2/3
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisWithdrawnNCT00502294Phase 3
- A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00502112Phase 1
- Safety and Tolerability of Rituximab in Neuromyelitis OpticaCompletedNCT00501748Phase 1
- A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18CompletedNCT00500058Phase 1
- Cord Blood Expansion on Mesenchymal Stem CellsCompletedNCT00498316Phase 1
- Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque PsoriasisCompletedNCT00493324Phase 4
- Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic SyndromeCompletedNCT00488436Phase 4
- Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic PurpuraCompletedNCT00486421Early Phase 1